OncoGen has developed a proprietary technology that creates novel monoclonal antibodies (mAbs), which are able to detect markers unique to cancer cells. At the present, all commercially available antibodies in cancer therapy are unable to identify only cancer cells, which results into their inherent toxicity. Furthermore, all current antibodies are unable to detect cancer accurately at an early stage when it is mostly curable. OncoGen can have an impact on both areas. The company has generated novel and highly specific mAbs which, in preliminary clinical trials, showed that are able to target only cancer cells at very low concentrations.